| Literature DB >> 24287999 |
Shaukat Ali1, Nasir Rasool, Aman Ullah, Faiz-ul-Hassan Nasim, Asma Yaqoob, Muhammad Zubair, Umer Rashid, Muhammad Riaz.
Abstract
A series of various novel 4-arylthiophene-2-carbaldehyde compounds were synthesized in moderate to excellent yields via Suzuki-Miyaura cross-coupling with different arylboronic pinacol esters/acids. The synthesized products were screened for their antibacterial, haemolytic, antiurease, and nitric oxide (NO) scavenging capabilities and interestingly, almost all products turned out to have good activities. 3-(5-Formyl-thiophene-3-yl)-5-(trifloromethyl)benzonitrile (2d) revealed excellent antibacterial activity, showing an IC50 value of 29.7 µg/mL against Pseudomonas aeruginosa, compared to the standard drug streptomycin with an IC50 value 35.2 µg/mL and was also found to be the best NO scavenger, with an IC50 value of 45.6 µg/mL. Moreover, 4-(3-chloro-4-fluoro-phenyl)thiophene-2-carbaldehyde (2i) exhibited a superior haemolytic action and an outstanding urease inhibition, showing an IC50 value of 27.1 µg/mL.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24287999 PMCID: PMC6270011 DOI: 10.3390/molecules181214711
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of 4-arylthiophene-2-carbaldehydes 2a–j.
Synthesis of 4-arylthiophene-2-carbaldehydes.
| Entry | ArylBoronic Acids/Esters | Products | Solvent/H2O (4:1) | Yields% |
|---|---|---|---|---|
| 1 |
|
| Toluene | 67 |
| 2 |
|
| 1,4-Dioxane | 64 |
| 3 |
|
| 1,4-Dioxane | 70 |
| 4 |
|
| 1,4-Dioxane | 66 |
| 5 |
|
| 1,4-Dioxane | 62 |
| 6 |
|
| Toluene | 64 |
| 7 |
|
| 1,4-Dioxane | 57 |
| 8 |
|
| 1,4-Dioxane | 71 |
| 9 |
|
| 1,4-Dioxane | 37 |
| 10 |
|
| 1,4-Dioxane | 40 |
| 11 |
|
| 1,4-Dioxane | 69 |
Antibacterial activity of synthetic compounds at 25 µg/mL *.
| Compound | Gram Positive Bacteria | Gram Negative Bacteria | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| 36.6 ± 0.4 | 23 ± 0.09 | 42 ± 0.02 | 18 ± 0.13 | 33 ± 0.05 | 33 ± 0.20 |
|
| 34 ± 0.01 | 36.2 ± 0.05 | 45 ± 0.019 | 14 ± 0.14 | 35 ± 0.01 | 34 ± 0.05 |
|
| 33 ± 0.01 | 28.3 ± 0.75 | 46 ± 0.02 | 32.5 ± 0.12 | 35 ± 0.15 | 30 ± 0.15 |
|
| 28 ± 0.2 | 22.4 ± 0.13 | 44 ± 0.02 | 32 ± 0.05 | 41 ± 0.05 | 22.2 ± 0.14 |
|
| 34 ± 0.05 | 24.4 ± 0.03 | 34 ± 0.04 | 9 ± 0.03 | 42 ± 0.7 | 36 ± 0.01 |
|
| 27 ± 0.08 | 36 ± 0.08 | 25 ± 0.06 | 22.5 ± 0.11 | 32 ± 0.01 | 32.2 ± 0.11 |
|
| 39.4 ± 0.05 | 28 ± 0.03 | 40 ± 0.041 | 32 ± 0.03 | 29 ± 0.19 | 30 ± 0.13 |
|
| 27.8 ± 0.12 | 36.5 ± 0.04 | 42 ± 0.04 | 16 ± 0.043 | 43 ± 0.105 | 33 ± 0.25 |
|
| 35.2 ± 0.01 | 27.10 ± 0.01 | 36 ± 0.16 | 26 ± 0.03 | 35 ± 0.2 | 29 ± 0.1 |
|
| 15 ± 0.034 | 34 ± 0.015 | 41.5 ± 0.002 | 29.3 ± 0.002 | 48 ± 0.05 | 33 ± 0.001 |
* Inhibition zone (in mm); data are expressed in the form of mean ± SD.
Antibacterial activity of synthetic compounds at 50 µg/mL *.
| Compound | Gram Positive Bacteria | Gram Negative Bacteria | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| 63 ± 0.18 | 61 ± 0.14 | 67.6 ± 0.001 | 47 ± 0.15 | 63 ± 0.18 | 61 ± 0.13 |
|
| 62.4 ± 0.1 | 59 ± 0.1 | 67 ± 0.01 | 38 0.18 | 62.4 ± 0.1 | 63 ± 0.25 |
|
| 64 ± 0.11 | 60 ± 0.01 | 60 ± 0.009 | 24 ± 0.17 | 64 ± 0.11 | 64 ± 0.5 |
|
| 63 ± 0.31 | 58 ± 0.35 | 67 ± 0.01 | 40.5 ± 0.19 | 63 ± 0.31 | 64 ± 0.05 |
|
| 58 ± 0.01 | 54 ± 0.17 | 60 ± 0.03 | 62 ± 0.01 | 58 ± 0.01 | 53 ± 0.12 |
|
| 61.4 ± 0.56 | 54 ± 0.23 | 64 ± 0.04 | 8 ± 0.01 | 61.4 ± 0.56 | 63 ± 0.11 |
|
| 59 ± 0.44 | 56 ± 0.24 | 56 ± 0.04 | 44.5 ± 0.19 | 59 ± 0.44 | 61 ± 0.16 |
|
| 59.4 ± 0.45 | 58 ± 0.22 | 67 ± 0.021 | 60 ± 0.24 | 59.4 ± 0.45 | 57 ± 0.01 |
|
| 58 ± 0.16 | 56 ± 0.5 | 66 ± 0.01 | 26 ± 0.023 | 58 ± 0.16 | 59.5 ± 0.25 |
|
| 65 ± 0.09 | 60 ± 0.05 | 69 ± 0.16 | 66 ± 0.43 | 65 ± 0.09 | 63 ± 0.1 |
|
| 55 ± 0.03 | 53 ± 0.001 | 63 ± 0.002 | 63 ± 0.002 | 55 ± 0.034 | 53 ± 0.001 |
* Inhibition zone (in mm); data are expressed in the form of mean ± SD.
Figure 1IC50 values of antibacterial activity.
Antiurease activity of synthesized compounds.
| Entry | %age Activity at 25 μg | %age Activity at 50 μg | IC50 (µg/mL) |
|---|---|---|---|
|
| 45 ± 0.0162 | 86.9 ± 0.012 | 27.9 |
|
| 35 ± 0.014 | 87.0 ± 0.084 | 32.2 |
|
| 44 ± 0.0042 | 87.8 ± 0.006 | 28.4 |
|
| 37 ± 0.0042 | 88.7 ± 0.005 | 31.2 |
|
| 44.5 ± 0.057 | 76.5 ± 0.05 | 29.2 |
|
| 42.3 ± 0.0007 | 80.2 ± 0.0017 | 30.0 |
|
| 42.5 ± 0.0070 | 87.2 ± 0.5 | 29.1 |
|
| 44 ± 0.084 | 86.4 ± 0.44 | 28.5 |
|
| 46.2 ± 0.0042 | 90.6 ± 0.05 | 27.1 |
|
| 2 ± 0.219 | 9.7 ± 0.2 | Zero |
|
| 47 ± 0.007 | 77 ± 0.015 | 27.5 |
Figure 2IC50 values of anti-urease activity.
NO scavenging activity of synthesized compounds.
| Compound | % Activity at 25 µg | % Activity at 50 µg | % Activity at 100 µg | IC50 µg/mL |
|---|---|---|---|---|
|
| 12 ± 0.037 | 33 ± 0.0035 | 48 ± 0.049 | 92.5 |
|
| 10 ± 0.02 | 45 ± 0.001 | 60 ± 0.021 | 66.6 |
|
| 18 ± 0.007 | 40 ± 0.038 | 55 ± 0.040 | 83.3 |
|
| 12.0 ± 0.025 | 58 ± 0.010 | 73 ± 0.0028 | 45.6 |
|
| −15 ± 0.04 | −12 ± 0.037 | 3 ± 0.0014 | NA |
|
| 5 ± 0.005 | 10 ± 0.028 | 25 ± 0.005 | NA |
|
| 13 ± 0.002 | 28 ± 0.007 | 43 ± 0.002 | NA |
|
| 13 ± 0.002 | 20 ± 0.025 | 35 ± 0.077 | NA |
|
| 12 ± 0.05 | 57 ± 0.0021 | 72 ± 0.009 | 46.1 |
|
| 15 ± 0.021 | 50 ± 0.024 | 65 ± 0.013 | 49.3 |
|
| 40 ± 0.038 | 61 ± 0.004 | 77 ± 0.001 | 56.33 |
Haemolytic activity of synthetic compounds 2a–j.
| Entry | Average ± SD | Entry | Average ± SD |
|---|---|---|---|
| 3.947 ± 0.078 | 2f | 6.083 ± 0.143 | |
| 5.003 ± 0.078 | 2g | 4.525 ± 0.075 | |
| 3.934 ± 0.095 | 2h | 3.487 ± 0.054 | |
| 3.306 ± 0.058 | 2i | 9.779 ± 0.095 | |
| 3.356 ± 0.075 | 2j | 4.135 ± 0.095 | |
| 99.824 ± 0.536 |